A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis
{{output}}
Background: DMB-3115 is a biosimilar to Stelara (hereinafter referred to as ustekinumab). Objectives: To evaluate the clinical similarity of DM... ...
